even if it received ppp, and all it takes is eight minutes to get started. then we'll work with you to fill out your forms and submit the application; that easy. and if your business doesn't get paid, we don't get paid. getrefunds.com has helped businesses like yours claim over $2 billion but it's only available for a limited time. go to getrefunds.com, powered by innovation refunds. good afternoon, everybody. welcome to "power lunch. alongside kelly evans i'm tyler mathisen coming up the future of goldman sachs. david solomon on cnbc today saying asset and wealth management will be the new growth engines for the company, but will he be around to lead goldman to its next chapter? we'll discuss what's ahead for solomon and the bank. plus, target shares are moving higher. earnings beat but the outlook is weaker

we'll dig into the results and what the company is saying about the strength of the consumer let's get a look at these markets in the meantime. the dow still the only negative of the major averages down a quarter percent, s&p up a third and the nasdaq two-thirds and the russell small caps leading the way. >> let's dig deeper on the markets with dom chu and kristina partsinevelos dom, you first. >> speaking of the dow the under performers due in part to declines in goldman sachs and united health care goldman carries about a 7% wea weighting. the whole thing, 17% between the two stocks if not for those two the dow would be positive today. you will have more on the goldman story coming up. health care, one of the drags. more broadly, united health. a 9% drop in universal health services on the day after the hospital operator reportedly generally positive quarterly results, but profit forecast did fall shy of estimates. outside the s&p a down day for

acadia health care, operator of mental health and addiction treatment facilities more mixed results in a higher cost environment the best performing sector, real estate overall s&p 500 members, extra space and public storage out performing help from a smaller nons&p, and more generally positive results. seems like there's a lot of demand for folks hoarding and storing stuff off site with that in mind, i'm going to send things over to kristina partsinevelos here because real estate is one thing, but tech much more important from a sector perspective. >> i'll start with the crypto space because we're seeing shares of coinbase surging 13% without any major news catalyst. county is heading for the first back-to-back monthly gain since august the bounce doesn't appear to be supported by bitcoin because we can see bitcoin is up but about a percent right now.

another player is robinhood, its shares up over 4% right now, even though the sec has subpoenaed the firm over its crypto listings and platform operation. switching gears completely, i want to talk about norwegian cruise lines because its shares are down 11.5% on a wider than expected loss due to soaring fuel and labor costs it's not the same reaction for some other travel names right now. wynn resorts and expedia, see both wynn up 3% and expedia up over 2%. >> thank you very much. we begin this hour with goldman sachs, one of the key stories of the day shares trading lower as the company holds its second investor day in the company's 154-year history off nearly 3%, the stock right now. it comes as there are growing concerns about the execution of some of its businesses earlier on "squawk box" krae david solomon addressed some of the concerns with andrew ross sorkin. >> i think it's absolutely fair

that our execution around the consumer platforms hasn't been to the standard we would like it to be. we tried to do too much too quickly and our execution and some areas of this wasn't good and so what do you do? you correct that so, you know, that's what businesses do. there isn't a business that kind of goes through and doesn't have successes, but also some stumbles. >> and will those stumbles cause mr. solomon his job? let's get insight on goldman's future with paul, professor of communications at dartmouth school of business and a consultant in the late '90s. good to have you with us. >> thanks. great to be back with you guys. >> were you convinced this morning listening to the interview with mr. solomon, both that he has the right strategy to get goldman clicking and he's right guy to do it >> i don't feel confident on either front based on today. i mean it's really -- you have

to prove it with action over time, and one interview isn't going to change what has happened over the last couple years in terms of the way goldman has performed and what's happened to its reputation and image over the last decade for sure so still a long way to go. >> how much time does he have to do the turnaround that you think is needed? >> i don't think he's got much time i mean starting to get pressured from partners. if the culture is the same as i knew it, once partners start to rattle the cages, things are starting to go the wrong way for him. i think he could clearly turn it around seems sometimes like he's distracted with other things focusing on other things is not good for the image of the bank or him, and he needs to bear down pretty much on focusing on goldman and get it back to where it needs to be. >> the interesting thing is the humbling ways that organization, those of us formed by its reputation in the 2000s and '90s

when you worked with them, it had such gravitas it was the subject of the famous article claiming it brought down the entire economy and does it have the same status today and if not why and what would your advice be to get back to those days or accept maybe they're never going back >> yeah. it may be impossible to get back to those days. the mystique surrounding it, they still attract hundreds of people for every job they have open and it's still a sought-after employer, but it doesn't have that same mystique that only a handful of organizations in the world have. whether they can ever get back there or not is really dependent upon how they look at the world. part of their problem is they don't have a good grasp of how communications works in the 21st century. worrying about leaks when everybody has access to everything you need to be more transparent about what you're doing. they clearly can't go back to

the days when information was so tightly held as it was in the late '90s when, you know, i knew the organization but they need to find a way to thread that needle, to try to get goldman to be a more respected institution than it is today and for the leader of the organization, whether it's solomon or someone else, to have a little bit more of the gravitas that goes with being in that position. >> let's compare it with its arch rival morgan stanley, which kind of doubled down on asset and wealth management, which now seems like where goldman is going to put a lot of emphasis meantime goldman, over the past decade, went in arguably off brand into consumer finance and banking. is it too late now to turn this ship around and do what it needs to do? >> absolutely not. absolutely not. >> okay. >> i don't think so. look, this is one of the premier organizations in the world of people who work there, world

class, and, you know, if they have the right strategy and the right leadership, i'm convinced this organization can do anything it wants. and, you know, right now, this is what's successful for morgan stanley and i've also worked with morgan stanley in the past. but i think whether that's going to be the future and, you know, we'll have to wait and see goldman can get back into that business and crush it. i think the consumer business was a distraction, totally off brand from what i know about goldman, and if they were going to do it they needed today it at a higher and prestigious level than they did. >> did you hint you don't think we should, you know, take it to the bank the idea that wealth management is the future for goldman? >> i don't think it's the only thing that's going to bail them out here they need to do more than that goldman could get into wealth management and do better at it than just about anybody else, but then what happens within, you know, other things become

more important and the investment banking business comes back they can't get rid of the core businesses and the things that make this organization great, while they try to figure out ways to increase revenue in a tight marketplace. you have to -- your strategy has to transcend what's going on in the marketplace, right, to be successful goldman was always good at that and i can't imagine they're not going to figure out very quickly how to settle thelz and get back to business. >> paul, thank you for your time and thoughts today. >> thank you. let's keep it on goldman what does it mean for the stock in girard cassidy is here from rbc capital markets a hold and 370 price target great to see you again what were your takeaways from investor day today and how important is david solomon's future to resolving what company should be worth right now? >> kelly, thank you for having me on the show i would say one of the takeaways that investors saw today was

that over the last three years this company has delivered incredible book value for share and growth much better than its peer group and the shareholder returns have been better they also pointed out that they are a preeminent global investment bank with incredible quality and brand recognition. that all being said, though, they have the challenge of this consumer banking business which you were talking about with the prior person on the call here. i think what you're going to see is that they are going to need to make some tough decisions about this consumer banking business because they don't expect it to be profitable until about 2025 and this is when their peers are profitable in this credit card business and other type of point of sale lending. that's the issue it's taking away from what they have done really well and this albatross is something around the neck of goldman at this time. >> it seems in the metrics

you've cited there, some of them better than the peer group in return to shareholders and so forth, those are important things is goldman not getting credit for the things it's doing well, as its missteps in consumer banking have overshadowed them >> i think that's part of it that's a really good observation because i think you're right, there is maybe, you know, the distraction of the consumer banking business, but we also have to remember that this is a market dependent industry in which goldman is one of the best in, and so that is not something that market pace up for in terms of high valuations, as we all know, predictability of earnings is critical in achieving a high valuation and because they're in a market dependent business, of course the capital markets, that makes their earnings and returns more volatile year to year as you saw last year, they were quite low relative to 2021 when

they were incredibly high. that is one of the factors why i think the stock doesn't do as well as maybe a morgan stanley who has a more predictable earnings stream. >> simply put, if you own the stock, what would you do with it today if you didn't own the stock, what would you do >> i think it really comes down very straightforwardly to what is your outlook for the market over the next 12 to 18 months. if you think the market is going to go into a further correction, you want to be on the sidelines on a bank that is in that business on the other hand if you're positive on the market and bullish you want to own this this is a pure play on the capital markets. >> finally what about what charlie said last hour that he would buy it at one time tangible book and sell it at two? >> buy low sell high always works for most people, so i'm with you, kelly. that's a pretty smart strategy. >> girard cassidy, a pleasure. thanks so much today. >> you're welcome. coming up we're going it

turn our attention to the other big ceo interview of the day on cnbc, target ceo brian cornell weighing the on that company's quarter and the strength of the consumer the stock higher despite some wish-washy guidance and today is rare disease day we'll put the spotlight on companies working on treatments that could lead to major breakthroughs. here's a look at a couple etfs in that space. we'll be right bk.ac is ge aero, advancing flight for future generations. ♪ welcome to a new era of flight.

it's official, america. xfinity mobile is the fastest mobile service. ♪

and gives you unmatched savings with the best price for two lines of unlimited. only $30 a line per month. the fastest mobile service and major savings? can't argue with the facts. no wonder xfinity mobile is one of the fastest growing mobile services, now with over 5 million customers and counting. save hundreds a year over t-mobile, at&t and verizon. talk to our switch squad at your local xfinity store today.

welcome back let's check out shares of target at close to 3% today after a 14% drop over the past year and they beat system for the first time in a year in those earnings and saw holiday sales growth but did warn of continued slow down risk as consumers spend less on discretionary items. brian cornell was on cnbc today. >> while there has been softness in discretionary categories, we delivered $55 billion of revenue through discretionary categories in 2022. they're not going to zero but we have seen a consumer who is not spending the way they were during the pandemic. >> let's bring in deborah, finder and ceo of core sight research and top analyst at citi great to see you again a lot of people following the stock were a little concerned where target is heading but seem to have put some of those worse fears behind them. >> yeah. they had an analyst meeting and talked about their guidance for the year ahead in terms of

traffic, looking at, you know, comps and also margins and provided some details, but i think there is -- there are a lot of questions many have around the consumer, but also a lot around macro policy, which could impact that. >> all right so in an uncertain -- it goes back to what we were talking about with goldman if you think the market is going to do great own them is it that binary for a company like target. >> absolutely not. if you look at top line growth the story of '22 a lot was around inflation and traffic they're still talking about having great traffic inflation is abating in the past four months most of the key categories down over 200 basis points top line could be muted. as you look ne margins on the gross margins side -- and they've been the most public company around challenges with shrink merchandise without being paid for. many retailers are facing pressure around higher labor

costs. however, on the positive side, and they did talk about this, but i would say, you know, the details were scant and this is -- this could be the kind of, you know, where it does follow the bottom line in the interesting way around retail media networks and that is where you're working with vendors and you have the opportunity to monetize your digital shelf, not just the physical shelf. >> two questions back-to-back. one is how much are they going to have to discount to start moving general merchandise, number one, and how will that affect their business? and number two, is the question about -- take question number one first. >> that's actually a very important question because, you know, they were very transparent how bloated their inventories came in '22 around holiday i believe they said on the call discretionary inventories are down 13% there could be backed up not on

their balance sheet at this point. there have been inventory issues and they are very focused -- their customer is coming in, you know, multiple times a week about two. they're getting a good read and seem to have adjusted their balance between kind of, if you will, fashion, and, you know, discretionary and staples. even with categories like apparel, footwear, accessories, ther a bit more kind of weighted towards basic merchandise right now with a fashionable flair as it is target certainly i think they are -- they're being prudent in '23 and i think that, you know, that probably is right now from an investor sper perspective one people are more comfortable with. >> you kind of answered my second question which circled around inventory and whether they've made progress in what had been a bit of a sore point for them. >> yeah. they really ended up, you know, on the heavier side. their store side they very much talked about, which could have led -- it's an interesting

point -- to the very high shrink that they saw. with less inventory and shrink hopefully maybe less, that could set up an interesting story for this year which i don't think necessarily came out of the meeting today. >> deborah, what would your recommendation be to investors is target a name they should own? should they look to walmart? what's your -- >> i would say off mall more than mall. we are seeing this kind of, you know, you've got to eat, people go to the grocery store 2.1 times per week they have the traffic. they have the -- not just the weekend traffic but monday and tuesday traffic as well. i think with the discretionary kind of if you will merchandise at a walmart and target you're in great shape probably the most important is the windfall from bed, bath & beyond we are seeing a significant opportunity in the discretionary

category and these, you know, both walmart and target -- target from a mix has a higher percentage of home and so just looking at that, if i had to pick one i would pick targts over walmart because of home, because of the opportunity, you know, around retail networks i think they've been focused on shrink, brought inventories down and they didn't shy away from any questions. they really kind of addressed them head on which means they're probably doing that in their business as well. >> very interesting. that one company kind of -- i don't want to say going under struggling and the others redistributing the market share. thanks for your time today. >> thank you very much. ahead on our program, office race workers in europe and asia returning to the office at a much faster rate than here in the u.s. that story when "power lunch" returns.

we planned well for retirement, but i wish we had more cash. you think those two

have any idea? that they can sell their life insurance policy for cash? so they're basically sitting on a goldmine? i don't think they have a clue. that's crazy! well, not everyone knows coventry's helped thousands of people sell their policies for cash. even term policies. i can't believe they're just sitting up there! sitting on all this cash. if you own a life insurance policy of $100,000 or more, you can sell all or part of it to coventry. even a term policy. for cash, or a combination of cash and coverage, with no future premiums. someone needs to tell them, that they're sitting on a goldmine, and you have no idea! hey, guys! you're sitting on a goldmine! come on, guys! do you hear that? i don't hear anything anymore. find out if you're sitting on a goldmine. call coventry direct today at the number on your screen, or visit coventrydirect.com.

let's get you caught up on the markets. stocks mixed as you see right there. a lot going on in bonds so we're going to begin with rick santelli in chicago. rick >> yes the only maturity right now that has a lower or higher price and

a lower yield than yesterday are 30-year bonds. all maturities are drifting lower in yields. the last day of the month look at month to date ii two-year month to date, 420, up 60 basis points for the month. 10s at 3.51 up 40 basis points as you see and when was the last time 10s closed at 4% or higher i can tell you that day is easy, november 9th that was 112 days ago, 72 trading days ago, it's been a while. and if you look at europe, pretty much the same scenario, actually maybe leaving us higher in rates earlier in the session. bund yields at 37 basis points up on the month. they settle in january 228 gilts, 3.33, up 50 basis points. it's been a big month in the u.s. for rates but really been a

big month for the world in terms of rates back to you. >> great point thank you. turn to bob pisani at the new york stock exchange. bob, it's the dow in the red and everyone else positive or is that still the case? >> united health, merck, some of the other consumer staples weighing on the dow right now. the s&p to the upside. news in the middle of the day. "wall street journal" says apollo in talks to acquire aerospace parts maker iconic that moved in the middle of the day. but the big story here, you see the jump by arconic, how we have big games in the major tech names for february nvidia, huge mover in the semiconductors tesla up 22% meta up 19 ge health care has been a big winner near a new high, only public for a few months. big decliners for february, dominos, news corps, and some of the energy stocks like eog, conoco phillips also with oil

stock in the mid to high $70 range. s&p 500, let's just say down about 2% for the month of february but up about 4% for the overall year right now been choppy ending off the lows for february back to you. >> all right bob, thank you. kristina partsinevelos now has our cnbc news update kristina. >> thank you united nations inspectors have found uranium a particles at a uranium nuclear site by the associateded press the report refers to particles suggesting iran is not stockpiling significant amounts of uranium above the 60% level the discovery likely to increase tensions with the west. the commerce department is' sessing a policy that allows u.s. technology below the 5g level to be exported to huawei according to an official's testimony before a congressional panel. and in wales as they toured a fitness center, the prince and

princess of wales competed against each other in a virtual contest to see who could ride the furthest uppill in 45 seconds on stationary bikes. despite wearing high heels kate was declared the winner >> did anyone doubt that come on. >> i know. >> as it should be. >> should we take it off line? >> yeah. >> ahead on "power lunch," revenue regrowth telehealth stocks reporting a narrower than reported loss. the stock hit the highest level in more than year. speaking of the health space, rare disease day what progress has been made in treating the illnesses, which companies are leading the charge we have details after this ♪♪ inner voice (kombucha brewer): if i just stare at these payroll forms... my business' payroll taxes will calculate themselves. right? uhh...nope. intuit quickbooks helps you manage your payroll taxes, cheers!

with 100% accurate tax calculations guaranteed. ♪♪ we all have a purpose in life - a “why.” maybe it's perfecting that special place that you want to keep in the family... ...or passing down the family business... ...or giving back to the places that inspire you. no matter your purpose, at pnc private bank, we will work with you every step of the way to help you achieve it. so let us focus on the how. just tell us - what's your why?

♪♪ (swords clashing) just tell us - what's your why? -had enough? -no... arthritis. here. aspercreme arthritis. full prescription-strength? reduces inflammation? thank the gods. don't thank them too soon. kick pain in the aspercreme. in order for small businesses to thrive, they need to be smart... efficient... agile... and that's never been more important than it is right now. so for a limited time, comcast business is introducing small business savings. call now to get powerful internet for just $39 a month, with no contract, and a money back guarantee. all on the largest, fastest, reliable network. from the company that powers more businesses than anyone else. call and start saving today.

comcast business. powering possibilities. welcome back to "power lunch. today you rare disease day, taken together, 300 million worldwide are affected by more than 6,000 rare diseases and biotech and big pharma are taking notice. joining us with more on the companies working in this area, meg tirrell.

hi, meg. >> hey, kelly. this is a really important area for pharmaceutical companies and a growing area of importance, so we define rare diseases in the united states as affecting fewer than 200,000 people. that still seems fairly large and a lot of diseases targeted by pharmaceutical companies affect even fewer patients than that this is a market that in 2021 was stiestimated at $29 billion revenue for the industry that's expected to more than double by 2027 according to cowen estimates to $68 billion in terms of the companies working in this space, vircontext far suitcle has the cystic fibrosis drugs, that have been transformational for this disease. y astrazeneca and pfizer having the biggest market share but sarepta will surpass by

2027, working in muscular dystrophy. a few reasons why this area is appealing to pharmaceutical companies. it changed in 1983 with the passage of the orphan drug act essentially cowen points out there can be lower clinical risk if the diseases are understood there's more flexible pathways to market. sometimes they can get there more quickly with smaller clinical trials and a lot of flexibility when it comes to pricing, a lot of drugs can cost hundreds of thousands of dollars a year and they get market exclusivity in many cases. seven years of not having competition. so all those things put together make this a very important area for pharma and growing. >> meg, thank you very much. stick around as we continue to talk about rare disease. for more on the development of rare disease treatments let's bring in peter, ceo of the national organization for rare disorders, commonly known as nord and boston children's hospital dr. bottomer. hope i pronounced your last name

correctly. peter, meg touched on two things that i know are really important here one is that historically pharmaceutical companies haven't wanted to invest in rare drug treatments because they're too small. they can't get the payoff they get from other kinds of drugs. number one simply aren't enough cases number two, those drugs are often hugely expensive are we making progress on both of those fronts? >> great question. i think we are making progress on both of those fronts and yes, the populations are smaller. there are, you know, they are smaller than large diseases, but there are 7,000 rare diseases right now and when you start to take a look across the one in ten americans that are impacted by a rare disease the populations can get larger as we start to work more with the human genome project, if you

will, we are starting to see -- we are continuing to see small marks but opportunities in various areas where small biotechs are developing new therapies that not only work in the rare disease but then have multiple opportunities to work on other indications as they go forward. i think it's -- the orphan drug act has been a successful vehicle and i will say there were 38 drugs on the market that were developed by fda prior to 1983 and since then 65 and in the last year, 50% of the approvals were for rare diseases it's a growing market and it's -- it's a real opportunity and more and more pharma is taking a closer look at it. >> doctor, i see you nodding there. i was struck by the fact that such a high percentage of rare disease patients are children, and in many cases tragically, it

results in fatality. where are we making progress the most progress, and where are we lagging behind with respect to progress against these rare diseases in children >> thank you for the question and having me. i think it's important to recognize the efforts that have been ongoing for the last couple of years to advance diagnostics, new newborn screening is one example, to identify these patients as early as possible in their disease course i think another important initiative that is the designation of rare disease centers to bring together medical teams, physicians who work on rare diseases in a more coherent fashion and make better use of their expertise and knowledge and i think this is an important step in the right

direction. what we are missing is a more universal access to rare disease centers to provide access to children and families who live in rural areas, for example, there's some inequity there, and also making better use of the tools we already have available for diagnosising these patients earlier to provide potential life-saving therapies at an earlier station in their lives. >> meg, if i'm not mistaken we hear about smaller biotech companies that have promising treatments in these areas and they're talked about as acquisition targets. do they have high valuations could we expect major pharma companies to end up bringing more treatments and drugs to the market rewarding investors in these stocks as well >> yeah. absolutely i mean, for probably the last decade, it's been rare diseases and cancer drugs that pharma

companies have been eager to acquire, and actually if you look at the list of the companies with the largest market share, sanofi got there because they acquired genzime, a pioneer of the market, henry, one of the early ceos who has now passed away, pioneered this high price model but also developing medicines for rare disease. sanofi acquired them and that's how they got big astrazeneca acquired a biotech company working in rare diseases these have been popular takeout targets and expected to continue to be so it's a space that biotech investors are interested in as well. >> what makes something considered a rare disease? i'm reading stats here, i don't know if i'm correct, but if one in ten people in the u.s. have a rare disease that seems actually somewhat common, so can you explain how rare we're talking about? >> kelly, that's a great question i think that rare diseases is

really sort of a misnomer nowadays because when you look at the populations of being less than 200,000 and when you look at the fact that there are more than, 7,000 rare diseases, it'sa large market right now and we're seeing so much interest from an investment perspective - >> let me make sure i understand, to be considered rare less than 2,000 have to have the disease, it's now we've identified more than 7,000. >> 200,000 the population is under 200,000 to qualify as a rare disease and there's 7,000 of those plus. it is a fairly large market when you think one in ten americans is basically afflicted with some sort of rare disease take a look at your own company nbc and talk about it an you will see there are people within the organization that all have rare diseases. they don't talk about them as much as you hear about cancer and so on because they just have been very small, but now when we

aggregate all of them together the population, it's 30 million americans right now. that has a huge economic impact. last year, the gao estimated it was in the range of 400 to $600 billion impact on the economy. it's a growing market right now and it's a -- industry is very interested and we're seeing ha that in the number of drugs approved by the fda. >>ing me -- meg, you have a question >> i do. we hear stories about how incredible the diagnostic capabilities are now, where parents of sick kids are able to figure out what's driving their disease, but then sometimes it is so rare that you can't get biotech companies interested in it i'm wondering, how frequently do you see that, that our diagnostic capabilities through genome sequencing are so good, we know what's causing the disease, but it's too uncommon to attract biotech companies where is the window where that

happens and are you seeing ways of addressing that so that parents when they finally figure out what's wrong, we can get drugs start to get developed for them too >> thank you that's a great question. i think you're referring to the diagnostic odyssey when we look at the diagnostic odyssey and we look at the data, it takes up to five years, sometimes even longer, until the patient who initially developed signs and symptoms of a rare disease is brought to the specialist who will then order the tests or genome testing as an example so we need to make sure that we provide -- we move forward much smarter in addressing the diagnostic odyssey one approach is to bring gee nom micks closer to primary care physicians, informing and educating primary care physicians about rare diseases in general and also raising

awareness about rare diseases, but then also, making sure that our colleagues and some of the subspecialties make use of the these tools that we've available or refer the patient to a rare disease center for diagnostics i think this is still a long way to go. i think in my own experience it's a mixed experience. some patients come to attention very early due to the significance of the symptoms sometimes it takes still in some cases years until a diagnosis is finally made. >> fascinating conversation the intersection of science and commerce here. doctor, peter, and meg, thank you very much. still to come, china's oil demand is not regaining strength shipments remain at low levels we'll discuss even with crude rebounding somewhat today. $77 a barrel but as we head to break during february we've been celebrating black heritage through the stories of our cnbc teammates, contributors and leaders in business

here is ross brewer. >> we actually have more shared values than we really understand because so many of us face adversities or different trials and tribulations, not only based on race and gender and so what are those things that might feel like they hold us back, but actually they give us the strength to be who we really are and so outside my community i would love to have conversations about who we are at our core and then begin to share our lived experiences. and find those commonalties and realize race and gender have sometimes less to do with why we are not interacting with each other at points.

♪♪ for skin as alive as you are... don't settle for silver. harness the power of 7 moisturizers & 3 vitamins to smooth, heal, and moisturize your dry skin. gold bond. champion your skin. welcome back oil finally closing higher by about 2% pippa stevens here with more. >> it is closing higher and shaking off yesterday's losses we've been talking about how the rebound in chinese demand has been what's driving the bullish narrative and how that has yet to actually come to fruition i wanted to take a look in a little more detail in where that chinese demand stands and if you

look at this chart from kepler, you can see that oil bound for china in december, january, and then especially february was way down compared to the prior months what this shows, this is loading bound for china, not imports, it's a leading indicator of sorts because if that oil is being put on the ship in february it means the import numbers for march and april will be down. and so what this essentially says is that that demand has not materialized. >> it's not there. higher in november. >> exactly. >> part of the higher numbers in the fall was because china implemented a product export quota in an effort to spur their refineries because their demand was low, they were still under lockdown, and that was the calculated move by the government to give the refiners something to do so they have higher exports right now they also have the refiners going into maintenance in april and may which means at the very earliest we could start to see a rebound come june that is far away and if that

goes up in the back half of the year that could be counter acted on other side by a slow down in demand from the u.s. and europe. >> i feel like it's one of the most important things that just the price of oil underpinned by what you showed us to figure out whether the markets are going to rally more this year, whether we're going to have real demand, the inflation trajectory this is not just a leading indicator for food prices but for the global economy right now. >> giving how much oil and gas are inputs into every thing in all of these daelts points they all come back to oil at a level. >> do they have a theory why demand might be so week right now? >> one said that even though the lockdowns have been lifted, behavior doesn't change overnight. when ours were lifted people were hesitant to go out and our lockdowns were not as long as they were in china so it just doesn't happen overnight. you don't turn on the switch and behavior changes. >> you would think it would be the biggest revenge travel of all time >> i had the same question

where is the demand and why hasn't it materialized manufacturing is down and just people are saying it doesn't happen overnight just have to wait a little bit longer to see. >> very important. >> thanks. up next, hair care, car vere, self-care, key earnings mors in today's three stock lunch. what do you mean? these straps are mind-blowing! they collect hundreds of data points like hrv and rem sleep, so you know all you need for recovery. and you are? i'm an investor...in invesco qqq, a fund that gives me access to... nasdaq 100 innovations like... wearable training optimization tech. uh, how long are you... i'm done. i'm okay.

♪♪ inner voice (kombucha brewer): if i just stare at these payroll forms... my business' payroll taxes will calculate themselves. right? uhh...nope. intuit quickbooks helps you manage your payroll taxes, cheers! with 100% accurate tax calculations guaranteed.

time for "three stock lunch. we'll sip on movers today, hims and hers surging on a record quarter and positive guidance. advanced auto parts higher after topping estimates, and dish network going the other way after a service outage and a double downgrade at bank of america. here to help us trade all three, david wagner, portfolio manager. let's begin with hims and hers health it went cash flow positive.

>> i think the market has been somewhat surprised by the company's consistent ratio younger generation of generic prescriptions. thanks to their growth in cost management, they're raising their operating levers this past quarter was the first quarter the company was ebitda positive $100 million pretty interested in the company. >> david, it's a little warbly, your sound let's try to get advanced auto parts in here. tell us why not. >> there are not many things in the this world outside of the

cincinnati reds winning a playoff series that will -- the stock. six years of frustration here. a 50% discount problem with developments that often are built into the stock it just never happens. i believe it's going to continue to be a value trap last quarter the company talked down their margin guidance to the low end of the range haven't rectified the problem. please, please save yourself the frustration that many of us have felt >> let's get a quick thought finally on dish. >> yeah. i feel that this is really --

the number of downgrades that we see. it's hard to bet against charter. it feels like these options are opportunities for the long term. obviously the 5g wireless buildout with this name. if you look at verizon and that outlook -- the icing on the cake today is a cybersecurity breach, so i have no interest here >>. >> interest on dish. dave wagner thanks appreciate it. the rest of the world is getting back into the office faster than america is can you believe that we'll take a look at all the numbers under the microscope next family is here.

with models that fit any lifestyle. and innovative ways to make your e-tron your own. through elegant design and progressive technology. all the exhilaration, none of the compromise. the audi e-tron family. progress that moves you. if your business kept on employees through the pandemic, getrefunds.com can see if it may qualify for a payroll tax refund of up to $26,000 per employee, even if it received ppp, and all it takes is eight minutes to get started. then we'll work with you to fill out your forms and submit the application; that easy. and if your business doesn't get paid, we don't get paid. getrefunds.com has helped businesses like yours claim over $2 billion but it's only available for a limited time. go to getrefunds.com, powered by innovation refunds.

a ballet studio, an architecture firm... and homemade barbeque sauce. they're called 'small businesses.' but to the people who build them there's nothing 'small' about them. that's why at t-mobile for business... you'll save more than $1,000 versus verizon. and with price lock guarantee, we'll never raise your rate plan. so you can keep your focus on toe-turns and making sure the sauce is extra spicy. at t-mobile, there are no small businesses. ♪♪ what if you were a trendy apparel company facing an avalanche of demand? to ensure more customers can buy more sherpa-lined jackets,

you call ibm to automate your it infrastructure with ai . now your systems monitor themselves. what used to take hours takes minutes. and you have an ecommerce platform designed to handle sudden spikes in overall demand... as in actual overalls. ♪♪ welcome back to "power lunch. we reported on the pushbacks ceos have gotten on back to the office policies. now we're getting numbers on how the u.s. stacks up to the rest of the world dominic chu has put it under his microscope >> elsewhere around the world right now, there's a lot more appetite to go back into the office than here in the united states so jll, big commercial real estate company all over the

world, they have a good insight on just how many people are occupying offices around the world and around the country they put together some numbers the interesting part is how we stack up around the world. in the u.s., according to their data, a great story in the "wall street journal" today, about 40% to 60% occupancy of prepandemic levels that's where we're at right now. compare ta tho places in the middle east, asia, and it gets very interesting in the u.s., 40% to 60%. in the europe and the middle east, we're back to 70% to 90% of precovid levels in certain jurisdictions in asia, it's gone anywhere from 80% to 110%, 110% meaning there are effectively in certain cities in asia more people back in the office now. >> office jobs >> correct what's interesting about this is just what the evolution or the psychology is like around this now, there's also a case -- >> -- covid just lifted in

china. >> that was just china, right. there are certain places elsewhere in asia that have seen more appetite to come back to the office the interesting part will be the evolution in the u.s how many ceos will be like andy jassy and pushing people for five days a week >> i thought it was three. dom, thank you very much dom chu. >> thanks for watching "power lunch. >> "closing bell" starts right now. welcome to "closing bell." i'm scott wapner this make-or-break hour begins with stocks finishing a tough month with some critical weeks ahead for your money here is your scorecard with 60 minutes to go in regulation. will this be the day the s&p closes back above 4,000? we shall see and the 10-year hasn't moved above 4% since november. yields are on the move we begin with our "talk of the tape," the road ahead for the most popular stock in this